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Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications of phase III trials, assessing 
the safety and efficacy of the drugs of interest. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies five prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 40th prioritisation (July 2019), eleven drugs were filtered out of 570 identified and were sent 
to prioritisation. Of these, 6 drugs were ranked as ‘highly relevant’ by the expert panel, 5 as ‘relevant’ 
and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
No. Filtered Drugs – 40th prioritisation 3rd quarter 2019 Overall category 
1. Alpelisib (Piqray®, BYL719) for PIK3CA-mutated, hormone 
receptor (HR) – positive advanced breast cancer 
Highly relevant 
2. Overall survival with ribociclib (Kisqali®, LEE011) plus endocrine 
therapy in breast cancer 
Highly relevant 
3. Trastuzumab emtansine (Kadcyla®, T-DM1) for residual invasive 
HER2-positive breast cancer 
Highly relevant 
4. Apalutamide (Erleada®) for metastatic, castration-sensitive 
prostate cancer 
Highly relevant 
5. Enzalutamide (Xtandi®) with standard first-line therapy in 
metastatic prostate cancer 
Highly relevant 
6. Daratumumab (Darzalex®) plus lenalidomide and dexamethasone 
for untreated myeloma 
Relevant 
7. Pomalidomide (Imnovid®, Pomalyst®), bortezomib, and 
dexamethasone for patients with relapsed or refractory MM 
previously treated with lenalidomide 
Relevant 
8. Lenalidomide (Revlimid®) plus rituximab versus placebo plus 
rituximab in relapsed or refractory indolent lymphoma 
Highly relevant 
9. Maintenance olaparib (Lynparza®) for germline breast cancer gene 
(BRCA)-mutated metastatic pancreatic cancer 
Relevant 
10. Pembrolizumab (Keytruda®) versus chemotherapy for previously 
untreated, programmed death ligand 1 (PD-L1)-expressing, locally 
advanced or metastatic non-small-cell lung cancer (NSCLC) 
Highly relevant 
11. Venetoclax (Venclyxto®, Venclexta®,) and obinutuzumab in 
patients with chronic lymphocytic leukemia (CLL) and coexisting 
conditions 
Highly relevant 
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Breast cancer 
Alpelisib (Piqray®, BYL719) for PIK3CA-mutated, hormone 
receptor (HR) – positive advanced breast cancer 
Overview 
Drug Description 
an orally bioavailable, small-molecule, α-specific PI3K inhibitor that 
selectively inhibits p110α approximately 50 times as strongly as other 
isoforms 
Patient Indication 
men and postmenopausal women who had locally confirmed HR-positive, 
human epidermal growth factor receptor (HER) 2-negative advanced breast 
cancer, were eligible to receive further endocrine therapy after relapse or 
progression, and were receiving or had received aromatase inhibitor 
treatment in the context of neoadjuvant or adjuvant therapy or for advanced 
disease. 
Incidence in 
Austria 
breast cancer: 5,558 newly diagnosed women and 88 newly diagnosed men 
per year (2016), 119.4/100,000 women/year and 2.3/100,000 men/year 
(European Standard Population, 2013) [1] 
Current standard 
treatment 
the National Institute for Health and Care Excellence (NICE) guidelines for 
managing HR+, HER2- advanced breast cancer recommend the following 
treatments:  
endocrine therapy or chemotherapy:  
 offer endocrine therapy as a first-line treatment for the 
majority of patients with HR+ advanced breast cancer 
 offer chemotherapy as first-line treatment for patients with 
HR+ advanced breast cancer whose disease is imminently 
life-threatening or requires early relief of symptoms 
because of significant visceral organ involvement, 
providing they understand and are prepared to accept the 
toxicity 
 for patients with HR+ advanced breast cancer who have 
been treated with chemotherapy as their first-line 
treatment, offer endocrine therapy following the completion 
of chemotherapy  
 endocrine therapy:  
 offer an aromatase inhibitor (either non-steroidal or 
steroidal) to:  
o postmenopausal women with ER-positive breast 
cancer and no prior history of endocrine therapy 
o postmenopausal women with ER-positive breast 
cancer previously treated with tamoxifen  
 offer tamoxifen and ovarian suppression as first-line 
treatment to premenopausal and perimenopausal women 
with ER-positive advanced breast cancer not previously 
treated with tamoxifen 
 offer ovarian suppression to premenopausal and 
perimenopausal women who have previously been treated 
with tamoxifen and then experience disease progression 
 offer tamoxifen as first-line treatment to men with HR+ 
advanced breast cancer 
 chemotherapy:  
 on disease progression, offer systemic sequential therapy 
to the majority of patients with advanced breast cancer 
who have decided to be treated with chemotherapy 
 consider using combination chemotherapy to treat patients 
with advanced breast cancer for whom a greater 
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probability of response is important and who understand 
and are likely to tolerate the additional toxicity  
 for patients with advanced breast cancer who are not 
suitable for anthracyclines, systemic chemotherapy should 
be offered in the following sequence: 
o first line: single-agent docetaxel  
o second line: single-agent vinorelbine or 
capecitabine  
o third line: single-agent capecitabine or vinorelbine 
(whichever was not used as second-line 
treatment) 
 other second-line treatments:  
 everolimus: everolimus, in combination with exemestane, 
is recommended within its marketing authorisation, as an 
option for treating advanced HR+, HER2- breast cancer in 
postmenopausal women without symptomatic visceral 
disease that has recurred or progressed after a non-
steroidal aromatase inhibitor. Everolimus is recommended 
only if the company provides it with the discount agreed in 
the patient access scheme.  
 fulvestrant: fulvestrant is not recommended within its 
licensed indication, as an alternative to aromatase 
inhibitors for the treatment of oestrogen-receptor-positive, 
locally advanced or metastatic breast cancer in 
postmenopausal women whose cancer has relapsed on or 
after adjuvant anti-oestrogen therapy, or who have disease 
progression on anti-oestrogen therapy. Post-menopausal 
women currently receiving fulvestrant within its licensed 
indication as an alternative to aromatase inhibitors for the 
treatment of oestrogen-receptor-positive, locally advanced 
or metastatic breast cancer whose cancer has relapsed on 
or after adjuvant anti-oestrogen therapy, or who have 
disease progression on anti-oestrogen therapy, should 
have the option to continue treatment until they and their 
clinicians consider it appropriate to stop.  
 other third-line treatments:  
 eribulin: eribulin is recommended as an option for treating 
locally advanced or metastatic breast cancer in adults, only 
when:  
o it has progressed after at least 2 chemotherapy 
regimens (which may include an anthracycline or a 
taxane, and capecitabine) 
o the company provides eribulin with the discount 
agreed in the patient access scheme (this guidance 
is not intended to affect the position of patients 
whose treatment with eribulin was started within the 
NHS before this guidance was published; treatment 
of those patients may continue without change to 
whatever funding arrangements were in place for 
them before this guidance was published until they 
and their NHS clinician consider it appropriate to 
stop) [2]. 
Ongoing Phase III NCT02437318 (SOLAR-1) ongoing until 09/2020 [3] 
Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (05/2019) alpelisib is indicated in: 
o in combination with fulvestrant for the treatment of postmenopausal 
women, and men, with HR-positive, HER2-negative, PIK3CA-
mutated, advanced or metastatic breast cancer as detected by an 
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FDA-approved test following progression on or after an endocrine-
based regimen [4]. 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs  -  
Published articles (PubMed): 
NEJM; 380:1929-40, May 16, 2019 (André et al.): “Alpelisib for PIK3CA-Mutated, Hormone 
Receptor–Positive Advanced Breast Cancer” [5] 
Background  
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR) – positive, 
human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-specific 
inhibitor alpelisib has shown antitumor activity in early studies. 
 
Methods  
In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant 
(at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients 
with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy 
previously. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation 
status. The primary end point was progression- free survival, as assessed by the investigator, in the 
cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort 
without PIK3CAmutated cancer. Secondary end points included overall response and safety. 
 
Findings  
A total of 572 patients underwent randomization, including 341 patients with confirmed tumor-tissue 
PIK3CA mutations. In the cohort of patients with PIK3CA-mutated cancer, progression-free survival 
at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in 
the alpelisib–fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo–
fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001); in the 
cohort without PIK3CA-mutated cancer, the hazard ratio was 0.85 (95% CI, 0.58 to 1.25; posterior 
probability of hazard ratio <1.00, 79.4%). Overall response among all the patients in the cohort 
without PIK3CA-mutated cancer was greater with alpelisib–fulvestrant than with placebo–fulvestrant 
(26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 
35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 
3 or 4 were hyperglycemia (36.6% in the alpelisib–fulvestrant group vs. 0.7% in the placebo–
fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the 
alpelisib– fulvestrant group, as compared with 0.3% of those in the placebo–fulvestrant group; no 
diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and 
placebo owing to adverse events were 25.0% and 4.2%, respectively. 
 
Interpretation  
Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with 
PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine 
therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, 
NCT02437318.) 
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Overall survival with ribociclib (Kisqali®, LEE011) plus endocrine 
therapy in breast cancer  
Overview 
Drug Description 
ribociclib is a selective, orally available inhibitor of cyclin-dependent kinases 
4 and 6 (CDK4/6) 
Patient Indication 
premenopausal or perimenopausal women with HR–positive, HER2-
negative advanced breast cancer. 
Incidence in 
Austria 
breast cancer: 5,558 newly diagnosed women and 88 newly diagnosed men 
per year (2016), 119.4/100,000 women/year and 2.3/100,000 men/year 
(European Standard Population, 2013) 
Current standard 
treatment 
 treatment for patients with advanced breast cancer aims to slow 
disease progression, manage symptoms and improve quality of life 
 current practice for HR-positive breast cancer is usually focused on 
endocrine anti-oestrogen treatments before moving onto 
chemotherapy, unless the patient is resistant or has developed 
rapidly life-threatening disease 
 most premenopausal women have aggressive cancers requiring 
chemotherapy when there is visceral disease recurrence  
 treatment options for women with advanced HR-positive/HER2-
negative breast cancer include: 
- endocrine therapies – tamoxifen and ovarian suppression 
as first-line treatment to premenopausal and 
perimenopausal women with ER-positive advanced breast 
cancer not previously treated with tamoxifen 
- chemotherapy – single agents are recommended: 
anthracycline- or taxane-based regimens, capecitabine, 
vinorelbine, gemcitabine (with paclitaxel), 
cyclophosphamide, platinum-based treatments; eribulin 
(not recommended by NICE) 
- bisphosphonates – for women undergoing ovarian 
suppression and for treatment-related bone loss.  
- surgery or radiotherapy with adjuvant systemic therapy 
may be considered for patients with bone metastases and 
pain, or those with a single or small number of potentially 
resectable brain metastases, a good performance status 
and who have no or well-controlled other metastatic 
disease.  
Ongoing Phase III 
NCT02278120 (MONALEESA-7) until 12/2020 
NCT02422615 until 02/2020 
NCT01958021 until 08/2021 
NCT02941926 until 05/2021 
NCT03425838 until 10/2022 
NCT03096847 until 02/2020 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
according to product information (01/2019), ribociclib is indicated: 
 for the treatment of women with HR-positive, HER2-negative 
locally advanced or metastatic breast cancer in combination with 
an aromatase inhibitor or fulvestrant as initial endocrine-based 
therapy, or in women who have received prior endocrine 
therapy. In pre- or perimenopausal women, the endocrine 
therapy should be combined with a luteinising hormone-
releasing hormone (LHRH) agonist. 
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FDA 
according to label information (07/2018), ribociclib is indicated  in 
combination with: 
 an aromatase inhibitor for the treatment of pre/perimenopausal or 
postmenopausal women with HR-positive, HER2-negative 
advanced or metastatic breast cancer, as initial endocrine-based 
therapy; or  
 fulvestrant for the treatment of postmenopausal women with HR-
positive, HER2-negative advanced or metastatic breast cancer, as 
initial endocrine based therapy or following disease progression on 
endocrine therapy. 
Costs  
63 Kisqali® tablets (200 mg) = € 3,350.00 (ex-factory price) 
 
MONALEESA-7 trial patients (ribociclib group) received ribociclib at a dose 
of 600 mg, administered orally once daily for 21 consecutive days followed 
by 7 days off, for a complete cycle of 28 days → costs of € 3,350.00/cycle. 
Both groups received goserelin and either a nonsteroidal aromatase 
inhibitor or tamoxifen administered orally once daily continuously → 
additional costs. 
The median duration of exposure to trial treatment in the ribociclib group 
was approx. 2 years → approx. € 80,400.00. 
1.1.1 Published articles (PubMed): 
NEJM; available online June 4, 2019 (Im et al.): “Overall Survival with Ribociclib plus Endocrine 
Therapy in Breast Cancer” [6] 
Background  
An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 
6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free 
survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced 
hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast 
cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end 
point of overall survival. 
 
Methods  
We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy 
(goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated 
with the use of a stratified log-rank test and summarized with the use of Kaplan–Meier methods. 
 
Findings  
A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 
335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the 
placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall 
survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% 
confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the 
placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The 
survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was 
consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 
0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was 
balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The 
time from randomization to disease progression during receipt of second-line therapy or to death was 
also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or 
death, 0.69; 95% CI, 0.55 to 0.87). 
 
Interpretation  
This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy 
than with endocrine therapy alone among patients with advanced hormone-receptor–positive, HER2-
negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. 
(Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.) 
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Trastuzumab emtansine (Kadcyla®, T-DM1) for residual invasive 
HER2-positive breast cancer 
Overview 
Drug Description 
trastuzumab emtansine is an antibody–drug conjugate of trastuzumab and 
the cytotoxic agent emtansine, a maytansine derivative and microtubule 
inhibitor 
Patient Indication 
patients were eligible if they had HER2- positive, nonmetastatic, invasive 
primary breast cancer (clinical tumor stage T1 to T4, nodal stage N0 to N3, 
and metastasis stage M0 excluding clinical stage T1aN0 or T1bN0) at 
presentation and if residual invasive disease was detected pathologically in 
the surgical specimen of the breast or axillary lymph nodes after completion 
of taxane-based neoadjuvant chemotherapy administered with trastuzumab 
Incidence in 
Austria 
breast cancer: 5,558 newly diagnosed women and 88 newly diagnosed men 
per year (2016), 119.4/100,000 women/year and 2.3/100,000 men/year 
(European Standard Population, 2013) [1] 
Current standard 
treatment 
 NICE recommends to consider adjuvant therapy for all patients with 
early invasive breast cancer after surgery. Adjuvant chemotherapy 
or radiotherapy needs to be started as soon as clinically possible, 
within 31 days of completion of surgery in patients with early breast 
cancer having these treatments 
 trastuzumab, given at three-week intervals for one year or until 
disease recurrence (whichever is the shorter period), is 
recommended by NICE as a treatment option for women with early-
stage HER2-positive breast cancer following surgery, 
chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if 
applicable) 
 for patients with lymph node-positive breast cancer, NICE 
recommends docetaxel as part of an adjuvant chemotherapy 
regimen. Docetaxel, when given concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) as per its licensed indication, 
is recommended as an option for the adjuvant treatment of women 
with early node-positive breast cancer 
 for patients with early invasive breast cancer who have had a 
mastectomy and are at a high risk of local recurrence (include those 
with four or more positive axillary lymph nodes or involved resection 
margins), NICE recommends offering adjuvant chest wall 
radiotherapy [7]. 
Ongoing Phase III 
NCT01772472 (KATHERINE) until 04/2023 
NCT01966471 until 01/2024 
NCT01702571 until 09/2019 [3] 
Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (05/2019), trastuzumab is indicated as a 
single agent for: 
 the adjuvant treatment of patients with HER2-positive early breast 
cancer who have residual invasive disease after neoadjuvant 
taxane and trastuzumab-based treatment [4]. 
Approval 
status for 
other 
indications 
EMA 
according to product information (09/2018), trastuzumab emtansine is 
indicated: 
 as a single agent for the treatment of adult patients with HER2-
positive, unresectable locally advanced or metastatic breast cancer 
who previously received trastuzumab and a taxane, separately or 
in combination. Patients should have either: 
- received prior therapy for locally advanced or metastatic 
disease, or 
- developed disease recurrence during or within six months 
of completing adjuvant therapy [8]. 
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FDA 
according to label information (05/2019), trastuzumab is indicated as a 
single agent for: 
 the treatment of patients with HER2-positive, metastatic breast 
cancer who previously received trastuzumab and a taxane, 
separately or in combination. Patients should have either:  
- received prior therapy for metastatic disease, or  
- developed disease recurrence during or within six months 
of completing adjuvant therapy [4]. 
Costs  
Kadcyla® concentrate for solution for infusion (100 mg) = € 1,700.00 (ex-
factory  price) [9] 
 
KATHERINE trial patients assigned to the T-DM1 group received T-DM1 at 
a dose of 3.6 mg per kilogram of body weight intravenously every 3 weeks 
for 14 cycles.  
Assuming an average body weight of 70 kg, 252 mg would be needed for 
one dose, costing € 5,100.00 (costs for 14 cycles → approx. € 71,400.00)  
A loading dose of 8 mg of trastuzumab per kilogram was administered if 
more than 6 weeks had elapsed since the preceding dose of trastuzumab. 
Published articles (PubMed): 
NEJM; available online December 5, 2018 (Minckwitz et al.): “Trastuzumab Emtansine for 
Residual Invasive HER2-Positive Breast Cancer” [10] 
Background  
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus 
human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than 
those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate 
of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule 
inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with 
chemotherapy plus HER2-targeted therapy. 
 
Methods  
We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer 
who were found to have residual invasive disease in the breast or axilla at surgery after receiving 
neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients 
were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. The primary end 
point was invasive disease–free survival (defined as freedom from ipsilateral invasive breast tumor 
recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast 
cancer, distant recurrence, or death from any cause). 
 
Findings  
At the interim analysis, among 1486 randomly assigned patients (743 in the T-DM1 group and 743 
in the trastuzumab group), invasive disease or death had occurred in 91 patients in the T-DM1 group 
(12.2%) and 165 patients in the trastuzumab group (22.2%). The estimated percentage of patients 
who were free of invasive disease at 3 years was 88.3% in the T-DM1 group and 77.0% in the 
trastuzumab group. Invasive disease–free survival was significantly higher in the T-DM1 group than 
in the trastuzumab group (hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 
0.39 to 0.64; P<0.001). Distant recurrence as the first invasive-disease event occurred in 10.5% of 
patients in the T-DM1 group and 15.9% of those in the trastuzumab group. The safety data were 
consistent with the known safety profile of T-DM1, with more adverse events associated with T-DM1 
than with trastuzumab alone. 
 
Interpretation  
Among patients with HER2-positive early breast cancer who had residual invasive disease after 
completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 
50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hoffmann–La 
Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472.) 
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Prostate cancer 
Apalutamide (Erleada®) for metastatic, castration-sensitive 
prostate cancer  
Overview 
Drug Description 
apalutamide is an inhibitor of the ligand-binding domain of the androgen 
receptor 
Patient Indication 
patients with an adenocarcinoma of the prostate and distant metastatic 
disease documented on the basis of at least one lesion on bone scanning, 
with or without visceral or lymph-node involvement. 
Incidence in 
Austria 
5,245 newly diagnosed per year (2016), 138.3/100,000 men/year 
(European Standard Population, 2013) [11] 
Current standard 
treatment 
 for men with metastatic hormone-sensitive prostate cancer 
(mHSPC), NICE guidelines recommend: 
- bilateral orchidectomy or continuous luteinising-
hormone-releasing hormone (LHRH)-agonist therapy 
- anti-androgen monotherapy with bicalutamide; or 
- combined androgen blockade (not first-line) 
 NICE has also published an evidence summary for the off-label use 
of docetaxel in combination with androgen deprivation therapy 
(ADT) for the treatment of mHSPC. Docetaxel is licensed in the UK 
for the treatment of metastatic hormone-resistant prostate cancer. 
 a draft of an update to the NICE guideline for prostate cancer 
recommends offering docetaxel to people who do not have 
significant comorbidities, starting treatment within 12 weeks of 
starting ADT, to be administered in six 3-weekly cycles with or 
without daily prednisolone 
 although not currently recommended by NICE, abiraterone is 
licensed for the treatment of newly diagnosed, high risk mHSPC in 
adult men in combination with ADT plus prednisone or prednisolone 
[12]. 
Ongoing Phase III NCT02489318 (TITAN) until 07/2022 [3] 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
according to product information (03/2019), apalutamide is indicated: 
 in adult men for the treatment of non-metastatic castration-resistant 
prostate cancer (nmCRPC) who are at high risk of developing 
metastatic disease [8] 
FDA 
according to label information (02/2018), apalutamide is indicated: 
 for the treatment of patients with nmCRPC [4] 
Costs  
112 Erleada® tablets (60mg) = € 3,040.00 (ex-factory price) [9] 
 
TITAN trial patients received apalutamide at a dose of 240 mg per day 
(orally, added to ADT → additional costs); the median duration of the trial 
intervention was 20.5 months in patients of the apalutamide group.  
28 days of treatment = € 3,040.00, 20.5 months of treatment = € 62,320.00. 
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Published articles (PubMed): 
NEJM; available online May 31, 2019 (Chi et al.): “Apalutamide for Metastatic, Castration-Sensitive 
Prostate Cancer” [13] 
Background  
Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the 
addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic 
progression–free survival and overall survival as compared with placebo plus ADT among patients 
with metastatic, castration-sensitive prostate cancer has not been determined. 
 
Methods  
In this double-blind, phase 3 trial, we randomly assigned patients with metastatic, castration-sensitive 
prostate cancer to receive apalutamide (240 mg per day) or placebo, added to ADT. Previous 
treatment for localized disease and previous docetaxel therapy were allowed. The primary end points 
were radiographic progression–free survival and overall survival. 
 
Findings  
A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo 
plus ADT. The median age was 68 years. A total of 16.4% of the patients had undergone 
prostatectomy or received radiotherapy for localized disease, and 10.7% had received previous 
docetaxel therapy; 62.7% had high-volume disease, and 37.3% had low-volume disease. At the first 
interim analysis, with a median of 22.7 months of follow-up, the percentage of patients with 
radiographic progression–free survival at 24 months was 68.2% in the apalutamide group and 47.5% 
in the placebo group (hazard ratio for radiographic progression or death, 0.48; 95% confidence 
interval [CI], 0.39 to 0.60; P<0.001). Overall survival at 24 months was also greater with apalutamide 
than with placebo (82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for 
death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005). The frequency of grade 3 or 4 adverse events was 
42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the 
apalutamide group. 
 
Interpretation  
In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival 
and radiographic progression–free survival were significantly longer with the addition of apalutamide 
to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between 
the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, 
NCT02489318.) 
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Enzalutamide (Xtandi®) with standard first-line therapy in 
metastatic prostate cancer 
Overview 
Drug Description 
enzalutamide is an orally administered, small molecule inhibitor of the 
androgen receptor that is designed to overcome acquired resistance to first-
generation nonsteroidal antiandrogens 
Patient Indication men with mHSPC 
Incidence in 
Austria 
5,245 newly diagnosed per year (2016), 138.3/100,000 men/year 
(European Standard Population, 2013) [11] 
Current standard 
treatment  
 for men with mHSPC, NICE guidelines recommend: 
- bilateral orchidectomy or continuous luteinising-
hormone-releasing hormone (LHRH)-agonist therapy 
- anti-androgen monotherapy with bicalutamide; or 
- combined androgen blockade (not first-line) 
 NICE has also published an evidence summary for the off-label use 
of docetaxel (in combination with ADT) for the treatment of mHSPC. 
Docetaxel is licensed in the UK for the treatment of metastatic 
hormone-resistant prostate cancer. 
 a draft of an update to the NICE guideline for prostate cancer 
recommends offering docetaxel to people who do not have 
significant comorbidities, starting treatment within 12 weeks of 
starting ADT, to be administered in six 3-weekly cycles with or 
without daily prednisolone 
 although not currently recommended by NICE, abiraterone is 
licensed for the treatment of newly diagnosed, high risk mHSPC in 
adult men in combination with ADT plus prednisone or prednisolone 
[12]. 
Ongoing Phase III  
NCT02446405 (ENZAMET) until 12/2020 
NCT02677896 until 12/2023 
NCT02294461 until 03/2020 
NCT00268476 until 09/2024 [3] 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications  
EMA 
according to product information (01/2019), enzalutamide is indicated for 
 the treatment of adult men with high-risk non-metastatic castration-
resistant prostate cancer (CRPC)  
 the treatment of adult men with metastatic CRPC who are 
asymptomatic or mildly symptomatic after failure of ADT in whom 
chemotherapy is not yet clinically indicated  
 the treatment of adult men with metastatic CRPC whose disease 
has progressed on or after docetaxel therapy [8]. 
FDA 
according to label information (07/2018), enzalutamide is indicated for 
 the treatment of patients with CRPC [4]. 
Costs  
112 Xtandi® soft capsules (40 mg) = € 2,895.35 (ex-factory price) [9] 
 
ENZAMET trial patients received enzalutamide at a dose of 160 mg until the 
occurrence of clinical disease progression or prohibitive toxic effects. 
Based on the trial regimen, 28 days of enzalutamide treatment would cost 
€ 2,895.35. 
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Published articles (PubMed): 
NEJM; available online June 2, 2019 (Davis et al.): “Enzalutamide with Standard First-Line 
Therapy in Metastatic Prostate Cancer” [14] 
Background  
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in 
men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to 
testosterone suppression, with or without early docetaxel, will improve survival in men with 
metastatic, hormone-sensitive prostate cancer. 
 
Methods  
In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone 
suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy 
(standard-care group). The primary end point was overall survival. Secondary end points included 
progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical 
progression-free survival, and adverse events. 
 
Findings  
A total of 1125 men underwent randomization; the median follow-up was 34 months. There were 102 
deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio, 0.67; 
95% confidence interval [CI], 0.52 to 0.86; P = 0.002). Kaplan–Meier estimates of overall survival at 
3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) 
in the standard-care group. Better results with enzalutamide were also seen in PSA progression-free 
survival (174 and 333 events, respectively; hazard ratio, 0.39; P<0.001) and in clinical progression-
free survival (167 and 320 events, respectively; hazard ratio, 0.40; P<0.001). Treatment 
discontinuation due to adverse events was more frequent in the enzalutamide group than in the 
standard-care group (33 events and 14 events, respectively). Fatigue was more common in the 
enzalutamide group; seizures occurred in 7 patients in the enzalutamide group (1%) and in no 
patients in the standard-care group. 
 
Interpretation  
Enzalutamide was associated with significantly longer progression-free and overall survival than 
standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone 
suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, 
especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical 
Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; 
ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-
42.)  
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Lenalidomide (Revlimid®) plus rituximab versus placebo plus 
rituximab in relapsed or refractory indolent lymphoma 
Overview 
Drug Description 
lenalidomide is an immunomodulatory drug that binds to the cereblon E3 
ubiquitin ligase complex, resulting in ubiquitination of the transcription 
factors Aiolos and Ikaros, leading to antilymphoma effects. 
Patient Indication 
patients with marginal zone lymphoma (MZL) or follicular lymphoma (FL) 
(grades 1 to 3a) requiring treatment per investigator assessment; at least 
one prior chemotherapy, immunotherapy, or chemoimmunotherapy and 
two or more previous doses of rituximab; and relapsed, refractory, or 
progressive disease and not rituximab refractory disease 
Incidence in 
Austria 
NHLs: 1,133 newly diagnosed per year (2016), 15.5/100,000 persons/year 
(European Standard Population, 2013) 
The most common indolent NHL types, FL and MZL, account for 22% and 
7% of adult NHL, respectively. 
Current standard 
treatment 
 FL usually grows slowly. Although it is difficult to cure, it is usually 
kept under control for many years, with treatment needed only 
occasionally 
 once the condition has progressed to the extent that patients need 
treatment, many have first-line induction with rituximab in 
combination with chemotherapy (R-chemotherapy) that induces a 
response in most people. This is followed by rituximab maintenance 
therapy. Other patients are treated with rituximab alone, without the 
addition of chemotherapy.  
 second-line treatment for FL depends on the timing of relapse 
following first-line treatment and the chemotherapy agents used 
first-line 
- R-chemotherapy should be offered to patients who are 
rituximab-naïve, and should also be given if the patient had 
previously responded to rituximab 
- disease that remains under control for some time on 
rituximab maintenance, or after it has stopped, is likely to 
be treated with further R-chemotherapy (in combination 
with another chemotherapy agent) in preference to 
bendamustine monotherapy 
- rituximab monotherapy, within its marketing authorisation, 
is recommended as an option for the treatment of people 
with relapsed or refractory stage III or IV follicular non-
Hodgkin's lymphoma, when all alternative treatment 
options have been exhausted 
- in clinical practice, bendamustine monotherapy may be 
offered to patients with FL that does not respond to 
induction treatment with R-chemotherapy, or for disease 
that relapses early-on in the 2-year rituximab maintenance 
period. However, NICE was unable to recommend the use 
in the NHS of bendamustine for the treatment of indolent 
non-Hodgkin's lymphoma that is refractory to rituximab or a 
rituximab-containing regimen because no evidence 
submission was received from the manufacturer or sponsor 
of the technology. 
- Y-Ibritumomab radio-immunotherapy may be offered to 
patients with relapsed FL, especially those who are 
refractory to rituximab or chemotherapy and for those who 
are intolerant or unwilling to have further chemotherapy.  
- In August 2017, NICE recommended obinutuzumab in 
combination with bendamustine followed by obinutuzumab 
maintenance as an option for treating adults with refractory 
follicular lymphoma that did not respond or progressed 
during or up to 6 months after treatment with rituximab or a 
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rituximab-containing regimen, if the conditions in the 
managed access agreement for obinutuzumab are 
followed. 
- NCCN guidelines recommend chemoimmunotherapy, 
rituximab monotherapy, lenalidomide +/- rituximab, 
radioimmunotherapy, idelalisib, or fludarabine + rituximab. 
Ongoing Phase III 
NCT01938001 (AUGMENT) until 12/2021 
NCT02390869 until 03/2022 
NCT01996865 until 07/2024 
NCT01865110 until 03/2024 
Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (05/2019), lenalidomide is indicated for the 
treatment of: 
 previously treated FL, in combination with a rituximab product 
 previously treated MZL, in combination with a rituximab product  
Approval 
status for 
other 
indications 
EMA 
according to product information (06/2019), lenalidomide is indicated in 
 MM: 
- as monotherapy for the maintenance treatment of adult 
patients with newly diagnosed MM who have undergone 
ASCT 
- as combination therapy with dexamethasone, or 
bortezomib and dexamethasone, or melphalan and 
prednisone for the treatment of adult patients with 
previously untreated MM who are not eligible for 
transplant.  
- in combination with dexamethasone for the treatment of 
MM in adult patients who have received at least one prior 
therapy. 
 myelodysplastic syndromes (MDS):  
- as monotherapy for the treatment of adult patients with 
transfusion-dependent anaemia due to low- or 
intermediate-1-risk MDS associated with an isolated 
deletion 5q cytogenetic abnormality when other 
therapeutic options are insufficient or inadequate.  
 mantle cell lymphoma (MCL): 
- as monotherapy for the treatment of adult patients with 
relapsed or refractory MCL. 
FDA 
according to label information (05/2019), lenalidomide is indicated for the 
treatment of: 
 MM in combination with dexamethasone  
 MM, as maintenance following autologous HSCT 
 transfusion-dependent anaemia due to low- or intermediate-1-risk 
MDS associated with a deletion 5q abnormality with or without 
additional cytogenetic abnormalities  
 MCL in patients whose disease has relapsed or progressed after 
two prior therapies, one of which included bortezomib. 
Costs  
21 Revlimid® hard capsule 20 mg = € 6,093.50 (ex-factory price) 
 
Patients of the AUGMENT trial (lenalidomide + rituximab group) received 
oral lenalidomide at a dose of 20 mg daily on days 1-21 (plus intravenous 
rituximab → additional costs). Treatment continued for 12 cycles or relapse, 
progressive disease, withdrawal of consent, or unacceptable toxicity. 
According to the AUGMENT trial regimen, one month of lenalidomide 
treatment would cost € 6,093.50 (12 cycles → € 73,122.00). 
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Published articles (PubMed): 
J Clin Oncol 37:1188-1199; 2019 (Leonard et al.): “AUGMENT: A Phase III Study of Lenalidomide 
Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma” [15] 
Background  
Patients with indolent non-Hodgkin lymphoma typically respond well to first-line 
immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest 
the immunomodulatory agent lenalidomide could increase the activity of rituximab. 
 
Methods  
A phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab 
was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. 
Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in 
cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per 
independent radiology review. 
 
Findings  
A total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo 
plus rituximab (n = 180). Infections (63% v. 49%), neutropenia (58% v. 23%), and cutaneous 
reactions (32% v. 12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 
neutropenia (50% v. 13%) and leukopenia (7% v. 2%) were higher with lenalidomide plus rituximab; 
no other grade 3 or 4 adverse event differed by 5% or more between groups. Progression-free 
survival was significantly improved for lenalidomide plus rituximab versus placebo plus rituximab, 
with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P < .001) and median duration of 39.4 months (95% 
CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to 16.7 months), respectively. 
 
Interpretation  
Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an 
acceptable safety profile. 
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Lung cancer 
Pembrolizumab (Keytruda®) versus chemotherapy for previously 
untreated, programmed death ligand 1 (PD-L1)-expressing, locally 
advanced or metastatic non-small-cell lung cancer (NSCLC) 
Overview 
Drug Description pembrolizumab is a humanised IgG4 monoclonal antibody against PD-1 
Patient Indication 
patients with locally advanced or metastatic NSCLC and a PD-L1 tumour 
proportion score (TPS) of 1% or greater, without a sensitizing epidermal 
growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase 
(ALK) translocation and who had received no previous therapy for locally 
advanced or metastatic disease 
Incidence in 
Austria 
cancer of the trachea, lung and bronchia: 4,877 newly diagnosed per year 
(2016), 57.3/100,000 persons/year (European Standard Population, 2013) 
[16]. NSCLC is the most common type of lung cancer (85-90% of lung 
cancer cases). 
Current standard 
treatment 
 the aim of treatment for locally advanced or metastatic NSCLC is to 
prolong survival, improve quality of life, and control disease-related.  
 current guidelines recommend that chemotherapy should be 
offered to patients with stage IV NSCLC and good performance 
status (WHO 0 or 1 or a Karnofsky score of 80–100) 
 induction chemotherapy for advanced NSCLC should be a 
combination of a single third generation drug (docetaxel, 
gemcitabine, paclitaxel, or vinorelbine) plus a platinum drug (either 
carboplatin or cisplatin) 
 if patients cannot tolerate a platinum combination (or are WHO 
performance status 2), single agent chemotherapy with a third 
generation drug is recommended 
 in the first and subsequent treatment line setting, afatinib, erlotinib, 
and gefitinib (not recommend by NICE) are all options for epidermal 
growth factor receptor tyrosine kinase mutation (EGFR-TK) positive 
metastatic NSCLC patients  
 pemetrexed in combination with cisplatin is recommended if the 
tumour has been confirmed as adenocarcinoma or large-cell 
carcinoma on the basis of best survival figures and toxicity profile. 
 pemetrexed is recommended as maintenance therapy after 
treatment with platinum-based chemotherapy in combination with 
gemcitabine, paclitaxel and docetaxel (switch maintenance) if the 
tumour is adenocarcinoma or large-cell carcinoma 
 it is recommended that patients progressing after first line 
chemotherapy be offered docetaxel or erlotinib monotherapy as a 
second line treatment option, or crizotinib for previously treated 
ALK-positive advanced NSCLC, though this is not currently 
recommended by NICE [17]. 
Ongoing Phase III 
NCT02220894 (KEYNOTE-042) until  03/2021 
NCT02142738 until 05/2020 
NCT03302234 until 02/2024 
NCT03631199 until 10/2022 
NCT03976362 until 05/2024 
NCT03950674 until 01/2020 
NCT03875092 until 02/2021 
NCT03850444 until 03/2021 
NCT03829332 until 03/2024 
NCT03302234 until 02/2024 
NCT02775435 until 02/2021 [3] 
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Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (06/2019), pembrolizumab is indicated:  
 as a single agent for the first-line treatment of patients with NSCLC 
expressing PD-L1 (TPS ≥1%) as determined by an FDA-approved 
test, with no EGFR or ALK genomic tumor aberrations, and is:  
- stage III where patients are not candidates for surgical 
resection or definitive chemoradiation, or  
- metastatic [4]. 
Approval 
status for 
other 
indications 
EMA 
according to product information (05/2019), pembrolizumab is indicated  
 as monotherapy for the treatment of advanced (unresectable or 
metastatic) melanoma in adults 
 as monotherapy for the adjuvant treatment of adults with Stage III 
melanoma and lymph node involvement who have undergone 
complete resection 
 as monotherapy for the first-line treatment of metastatic NSCLC in 
adults whose tumours express PD-L1 with a ≥ 50% TPS with no 
EGFR or ALK positive tumour mutations 
 in combination with pemetrexed and platinum chemotherapy for the 
first-line treatment of metastatic non-squamous NSCLC in adults 
whose tumours have no EGFR or ALK positive mutations 
 in combination with carboplatin and either paclitaxel or nab-
paclitaxel for the first-line treatment of metastatic squamous 
NSCLC in adults 
 for the treatment of locally advanced or metastatic NSCLC in adults 
whose tumours express PD-L1 with a ≥ 1% TPS and who have 
received at least one prior chemotherapy regimen (patients with 
EGFR or ALK positive tumour mutations should also have received 
targeted therapy before receiving pembrolizumab  
 as monotherapy for the treatment of adult patients with relapsed or 
refractory classical Hodgkin lymphoma (cHL) who have failed ASCT 
and brentuximab vedotin (BV), or who are transplant-ineligible and 
have failed BV 
 as monotherapy for the treatment of locally advanced or metastatic 
urothelial carcinoma (UC) in adults who have received prior 
platinum-containing chemotherapy  
 as monotherapy for the treatment of locally advanced or metastatic 
UC in adults who are not eligible for cisplatin-containing 
chemotherapy and whose tumours express PD-L1 with a combined 
positive score (CPS) ≥ 10  
 as monotherapy for the treatment of recurrent or metastatic head 
and neck squamous cell carcinoma (HNSCC) in adults whose 
tumours express PD-L1 with a ≥ 50%TPS and progressing on or 
after platinum-containing chemotherapy [8]. 
FDA 
according to label information (06/2019), pembrolizumab is indicated in: 
 melanoma: 
- for the treatment of patients with unresectable or metastatic 
melanoma 
- for the adjuvant treatment of patients with melanoma with 
involvement of lymph node(s) following complete resection 
 NSCLC: 
- in combination with pemetrexed and platinum 
chemotherapy, as first-line treatment of patients with 
metastatic nonsquamous NSCLC, with no EGFR or ALK 
genomic tumor aberrations 
- in combination with carboplatin and either paclitaxel or 
paclitaxel protein-bound, as first-line treatment of patients 
with metastatic squamous NSCLC 
- as a single agent for the treatment of patients with 
metastatic NSCLC whose tumors express PD-L1 (TPS 
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≥1%) as determined by an FDA-approved test, with disease 
progression on or after platinum-containing chemotherapy 
 head and neck squamous cell cancer (HNSCC): 
- in combination with platinum and FU for the first-line 
treatment of patients with metastatic or with unresectable, 
recurrent HNSCC 
- as a single agent for the first line treatment of patients with 
metastatic or with unresectable, recurrent HNSCC whose 
tumors express PD-L1 (CPS) ≥1 as determined by an 
FDA-approved test 
- as a single agent for the treatment of patients with 
recurrent or metastatic HNSCC with disease progression 
on or after platinum-containing chemotherapy 
 classical Hodgkin lymphoma (cHL):  
- for the treatment of adult and pediatric patients with 
refractory cHL, or who have relapsed after 3 or more prior 
lines of therapy 
 primary mediastinal large B-cell lymphoma (PMBCL): 
- for the treatment of adult and pediatric patients with 
refractory PMBCL, or who have relapsed after 2 or more 
prior lines of therapy (limitations of use: pembrolizumab is 
not recommended for treatment of patients with PMBCL 
who require urgent cytoreductive therapy) 
 UC:  
- for the treatment of patients with locally advanced or 
metastatic UC who are not eligible for cisplatin-containing 
chemotherapy and whose tumors express PD-L1  (CPS 
≥10) as determined by an FDA-approved test, or in patients 
who are not eligible for any platinum-containing 
chemotherapy regardless of PD-L1 status 
- for the treatment of patients with locally advanced or 
metastatic UC who have disease progression during or 
following platinum-containing chemotherapy or within 12 
months of neoadjuvant or adjuvant treatment with platinum-
containing chemotherapy 
 microsatellite instability-high cancer (MSI-H):  
- for the treatment of adult and pediatric patients with 
unresectable or metastatic (MSI-H or mismatch repair 
deficient  
 solid tumors that have progressed following prior 
treatment and who have no satisfactory alternative 
treatment options or  
 colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and 
irinotecan (limitations of use: The safety and 
effectiveness of pembrolizumab in paediatric 
patients with MSI-H central nervous system 
cancers have not been established 
 gastric cancer:  
- for the treatment of patients with recurrent locally advanced 
or metastatic gastric or gastroesophageal junction 
adenocarcinoma whose tumors express PD-L1 (CPS ≥1) 
as determined by an FDA-approved test, with disease 
progression on or after two or more prior lines of therapy 
including fluoropyrimidine- and platinum-containing 
chemotherapy and if appropriate, HER2/neu-targeted 
therapy 
 cervical cancer: 
- for the treatment of patients with recurrent or metastatic 
cervical cancer with disease progression on or after 
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chemotherapy whose tumors express PD-L1 (CPS ≥1) as 
determined by an FDA-approved test 
 hepatocellular carcinoma (HCC): 
- for the treatment of patients with HCC who have been 
previously treated with sorafenib 
 Merkel cell carcinoma (MCC): 
- for the treatment of adult and paediatric patients with 
recurrent locally advanced or metastatic MCC 
 renal cell carcinoma (RCC): 
- in combination with axitinib, for the first-line treatment of 
patients with advanced RCC (accelerated approval) [4]. 
Costs  
Keytruda® 50 mg powder for concentrate for solution for infusion = € 
1,714.00 (ex-factory price) [9]. 
 
KEYNOTE-042 patients (pembrolizumab group) received pembrolizumab at 
a dose of 200 mg (€ 6,856.00 per dose) administered intravenously every 3 
weeks up to a maximum of 35 cycles. 
Published articles (PubMed): 
The Lancet; available online April 4, 2019 (Mok et al.): “Pembrolizumab versus chemotherapy for 
previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer 
(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial” [18] 
Background  
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients 
with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) 
tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment 
with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. 
 
Methods  
This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible 
patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-
cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern 
Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months 
or longer, and a PD-L1 TPS of 1% or greater. Randomisation was computer generated, accessed 
via an interactive voice-response and integrated web-response system, and stratified by region of 
enrolment (east Asia vs. rest of world), ECOG performance status score (0 vs. 1), histology 
(squamous vs. non-squamous), and PD-L1 TPS (≥50% vs. 1–49%). Enrolled patients were randomly 
assigned 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 
35 cycles or the investigator’s choice of platinum-based chemotherapy for four to six cycles. Primary 
endpoints were overall survival in patients with a TPS of 50% or greater, 20% or greater, and 1% or 
greater (one-sided significance thresholds, p=0.0122, p=0.0120, and p=0.0124, respectively) in the 
intention-to-treat population, assessed sequentially if the previous findings were significant. This 
study is registered at ClinicalTrials.gov, number NCT02220894. 
 
Findings  
From Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years 
[IQR 57–69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or 
chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 
50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median 
follow-up was 12.8 months. Overall survival was significantly longer in the pembrolizumab group than 
in the chemotherapy group in all three TPS populations (≥50% hazard ratio 0.69, 95% CI 0.56–0.85, 
p=0.0003; ≥20% 0.77, 0.64–0.92, p=0.0020, and ≥1% 0.81, 0.71–0.93, p=0.0018). The median 
survival values by TPS population were 20.0 months (95% CI 15.4–24.9) for pembrolizumab versus 
12.2 months (10.4–14.2) for chemotherapy, 17.7 months (15.3–22.1) versus 13.0 months (11.6–
15.3), and 16.7 months (13.9–19.7) versus 12.1 months (11.3–13.3), respectively. Treatment-related 
adverse events of grade 3 or worse occurred in 113 (18%) of 636 treated patients in the 
pembrolizumab group and in 252 (41%) of 615 in the chemotherapy group and led to death in 13 
(2%) and 14 (2%) patients, respectively. 
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Interpretation  
The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line 
therapy to patients with locally advanced or metastatic non-small-cell lung cancer without sensitising 
EGFR or ALK alterations and with low PD-L1 TPS. 
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Leukaemia 
Venetoclax (Venclyxto®, Venclexta®,) and obinutuzumab in 
patients with chronic lymphocytic leukemia (CLL) and coexisting 
conditions 
Overview 
Drug Description 
venetoclax is an orally administered, BCL2 homology domain 3 (BH3)–
mimetic compound that disrupts anti-apoptotic signaling through BCL2, 
thereby inducing programmed cell death of CLL cells 
Patient Indication 
patients with previously untreated CD20+ CLL that had been diagnosed in 
accordance with the criteria of the International Workshop on CLL and 
had been determined by the treating clinician and confirmed during the 
central screening process to require therapy (Binet stage C [low 
haemoglobin or platelet count from bone marrow infiltration of CLL cells] or 
symptomatic disease)  
Incidence in 
Austria 
leukaemia: 1,007 newly diagnosed per year (2016), 11.8/100,000 
persons/year (European Standard Population, 2013) [19] 
CLL: 5,600 newly diagnosed per year (Germany) [20]; CLL is the most 
common leukaemia in adults. 
Current standard 
treatment 
suggested treatment regimens for patients with CLL/SLL without 
del(17p)/TP53 mutation: 
 frail patients with significant comorbidity (not able to tolerate purine 
analogs) OR Patients age ≥65 y and younger patients with 
significant comorbidities: 
- preferred regimens: ibrutinib or venetoclax + obinutuzumab 
- other recommended regimens:  
 bendamustine + anti-CD20 monoclonal antibody 
(not recommended for frail patients) 
 chlorambucil + anti-CD20 monoclonal antibody 
 high-dose methylprednisolone (HDMP) + rituximab  
 ibrutinib + obinutuzumab  
 obinutuzumab  
 chlorambucil  
 rituximab  
 patients aged <65 years without significant comorbidities: 
- preferred regimen: ibrutinib 
- other recommended regimens: 
 bendamustine + anti-CD20 monoclonal antibody 
 FCR (fludarabine, cyclophosphamide, rituximab) 
 FR (fludarabine, rituximab) 
 HDMP + rituximab  
 ibrutinib + rituximab  
 venetoclax + obinutuzumab  
 PCR (pentostatin, cyclophosphamide, rituximab) 
[21].  
Ongoing Phase III 
NCT02242942 until 09/2021 
NCT03701282 until 10/2025 
NCT03462719 until 04/2024 
NCT02950051 until 01/2024 
NCT03836261 until 04/2024 
NCT03737981 until 06/2027 [3] 
Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (05/2019), venetoclax is indicated: 
 for the treatment of adult patients with CLL or small lymphocytic 
lymphoma (SLL) [4]. 
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Approval 
status for 
other 
indications 
EMA 
according to product information (12/2018), venetoclax is indicated: 
 in combination with rituximab for the treatment of adult patients with 
CLL who have received at least one prior therapy 
 as monotherapy for the treatment of CLL:  
- in the presence of 17p deletion or TP53 mutation in adult 
patients who are unsuitable for or have failed a B-cell 
receptor pathway inhibitor, or 
- in the absence of 17p deletion or TP53 mutation in adult 
patients who have failed both chemoimmunotherapy and a 
B-cell receptor pathway inhibitor [8]. 
FDA 
according to label information (05/2019), venetoclax is indicated: 
 in combination with azacitidine or decitabine or low-dose cytarabine 
for the treatment of newly-diagnosed acute myeloid leukemia (AML) 
in adults who are age 75 years or older, or who have comorbidities 
that preclude use of intensive induction chemotherapy [4]. 
Costs  
  14 Venclyxto® tablets 10 mg = € 74.94 
    7 Venclyxto® tablets 50 mg = €187.34 
    7 Venclyxto® tablets 100 mg = €374.69 
  14 Venclyxto® tablets 100 mg = € 749.38 
112 Venclyxto® tablets 100 mg 4x28 = €5,954.00 (ex-factory prices) [9] 
 
Trial patients: the treatment duration in both groups consisted of 12 cycles 
lasting 28 days each. The daily oral venetoclax regimen was initiated on day 
22 of cycle 1, starting with a 5-week dose ramp-up (1 week each of 20, 50, 
100, and 200 mg, then 400 mg daily for 1 week, costing € 2, 135.73), 
thereafter continuing at 400 mg daily until completion of cycle 12 
(5,954.00/cycle). In addition, costs for obinutuzumab incur. 
Published articles (PubMed): 
NEJM; available online June 4, 2019 (Fischer et al.): “Venetoclax and Obinutuzumab in Patients 
with CLL and Coexisting Conditions” [22] 
Background  
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia 
(CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions 
is not known. 
 
Methods  
In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and 
obinutuzumab in patients with previously untreated CLL and coexisting conditions. Patients with a 
score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, with higher 
scores indicating more impaired function of organ systems) or a calculated creatinine clearance of 
less than 70 ml per minute were randomly assigned to receive venetoclax–obinutuzumab or 
chlorambucil– obinutuzumab. The primary end point was investigator-assessed progression- free 
survival. The safety of each regimen was also evaluated. 
 
Findings  
In total, 432 patients (median age, 72 years; median Cumulative Illness Rating Scale score, 8; 
median creatinine clearance, 66.4 ml per minute) underwent randomization, with 216 assigned to 
each group. After a median follow-up of 28.1 months, 30 primary end-point events (disease 
progression or death) had occurred in the venetoclax–obinutuzumab group and 77 had occurred in 
the chlorambucil–obinutuzumab group (hazard ratio, 0.35; 95% confidence interval [CI], 0.23 to 0.53; 
P<0.001). The Kaplan–Meier estimate of the percentage of patients with progression- free survival 
at 24 months was significantly higher in the venetoclax–obinutuzumab group than in the 
chlorambucil–obinutuzumab group: 88.2% (95% CI, 83.7 to 92.6) as compared with 64.1% (95% CI, 
57.4 to 70.8). This benefit was also observed in patients with TP53 deletion, mutation, or both and 
in patients with unmutated immunoglobulin heavy-chain genes. Grade 3 or 4 neutropenia occurred 
in 52.8% of patients in the venetoclax–obinutuzumab group and in 48.1% of patients in the 
chlorambucil–obinutuzumab group, and grade 3 or 4 infections occurred in 17.5% and 15.0%, 
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respectively. All-cause mortality was 9.3% in the venetoclax–obinutuzumab group and 7.9% in the 
chlorambucil–obinutuzumab group. These differences were not significant. 
 
Interpretation  
Among patients with untreated CLL and coexisting conditions, venetoclax–obinutuzumab was 
associated with longer progression-free survival than chlorambucil– obinutuzumab. (Funded by F. 
Hoffmann–La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.) 
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